Vavici(TM) Announces Formation of First Comprehensive International Distribution System for Stem Cell Therapies
Posted on: Tuesday, 30 October 2007, 12:00 CDT
Vavici has announced its plans to create the first comprehensive international distribution network to bring life-changing stem cell therapies to healthcare providers and patients. The announcement was made in conjunction with Vavici's support of the Angel Ball, hosted by The G&P Foundation for Cancer Research, Monday, Oct. 29, 2007, in New York City at the New York Marriott Marquis.
"Stem cells have the potential to cure a broad range of chronic diseases, including cancer, heart disease, Alzheimer's, diabetes, multiple sclerosis and lupus," said Dr. Han S. Chiu, founder and CEO of Vavici.
As the first major worldwide, world-class distribution system to get therapies out of the laboratory and into doctors' offices and hospitals where patients can be treated, the Vavici distribution network will encompass:
Establishment of the highest quality advisory boards to ensure patient safety and appropriate protocols and standards for all stem cell therapies, services and provider facilities that are certified through Vavici internationally
Collaboration with major academic medical institutions and local regulatory authorities to ensure that all Vavici certified therapies exceed local guidelines
Creation of an international patient registry, comprehensive follow-up and education system to protect all patients and to provide them with appropriate disclosures
Distribution agreements and strategic relationships with all legitimate stem cell companies and institutions with groundbreaking technologies and services
Formation of an international network of certified Vavici affiliates that ensure quality care
The market for stem cell therapies is currently $16 million a year in the U.S. Within a decade, U.S. stem cell sales are projected to exceed $8.6 billion, according to RRY Publications market forecast. Vavici is poised to be the center of this nascent and exploding sector that is transforming the health care landscape.
About Vavici:
The name "Vavici" is composed of three words: Va (short for Vas, go in Spanish), Vi (short for Vie, life in French) and Ci (short for Chi, life force in Chinese). Go Life Force is the mandate for Vavici: unleashing the incredible life-changing power of stem cells in a global initiative to heal patients around the world.
Vavici is creating the first major comprehensive international distribution channel for stem cell therapies, building the bridge between research companies and healthcare providers such as academic medical centers, hospitals and large physicians groups that can bring these therapies to the patients who need them. Vavici is committed to being the industry leader in developing and implementing the most credible, ethical and practical procedures and protocols for stem cell processing and distribution. For more information, visit www.vavici.com.
Vavici™ is a registered trademark of Vavici, LLC.
Source: Business Wire
Related Articles
- United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients
- Research Provides Documentation That Tumor 'Stem-Like Cells' Exist In Benign Tumors
- iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
- Opexa Therapeutics Presents Myelin Reactive T-Cell Research at the International Society of Cell Therapy Annual Meeting
- An Investigational Study Released at ADA Showed That Initial Combination Therapy With JANUVIA(TM) (Sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients With Type 2 Diabetes
- Study Explores Stem-Progenitor Cells
- Berlin (Germany) Vascular Center Receives IRB Approval to Begin Clinical Trial Using Harvest Technologies' BMAC(TM) Point-of-Care System for Concentrating Autologous Adult Bone Marrow Stem Cells to Treat Patients With End-Stage Critical Limb Ischemia Who
- Statewide Blood Bank to Collect Umbilical Cord Blood: More Doctors Using Cord Stem Cells to Treat Patients With Leukemia
- PharmaFrontiers to Present Data on Adult Human T-Cell and Stem Cell Technologies at the International Society for Cellular Therapy Annual Meeting
- European Union's CHMP Adopts Positive Opinion For Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy For Certain Hepatitis C Patients With Genotype 1 and Low Viral Load
User Comments (0)

RSS Feeds